The PARP1 inhibitors talazoparib and olaparib can reverse the NE phenotype induced by TROP2 in PC cells and decrease tumor growth in TROP2-expressing NEPC xenografts [100]. The gene discussed is TACSTD2; the disease is pachyonychia congenita.